



A genomic portrait of the genetic architecture and regulatory impact of microRNA expression in response to infection

Katherine J. Siddle, Matthieu Deschamps, Ludovic Tailleux, et al.

Genome Res. 2014 24: 850-859 originally published online January 30, 2014

Access the most recent version at doi:[10.1101/gr.161471.113](https://doi.org/10.1101/gr.161471.113)

References This article cites 93 articles, 25 of which can be accessed free at:
<http://genome.cshlp.org/content/24/5/850.full.html#ref-list-1>

Creative Commons License This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genome.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

An advertisement banner with a teal background. On the left, the text reads "CRISPR and RNAi Genetic Screening. Your new superpower." In the center, there is a white-bordered box containing the words "LEARN MORE". On the right, there is a photograph of a woman wearing a red mask and a red cape, and the Cellecta logo, which consists of a green molecular structure and the word "CELLECTA" in white capital letters.

To subscribe to *Genome Research* go to:
<https://genome.cshlp.org/subscriptions>

© 2014 Siddle et al.; Published by Cold Spring Harbor Laboratory Press

Research

A genomic portrait of the genetic architecture and regulatory impact of microRNA expression in response to infection

Katherine J. Siddle,^{1,2,11} Matthieu Deschamps,^{1,2,3,11} Ludovic Tailleux,⁴ Yohann Nédélec,^{5,6} Julien Pothlichet,^{1,2} Geanncarlo Lugo-Villarino,^{7,8} Valentina Libri,⁹ Brigitte Gicquel,⁴ Olivier Neyrolles,^{7,8} Guillaume Laval,^{1,2} Etienne Patin,^{1,2} Luis B. Barreiro,^{6,10} and Lluís Quintana-Murci^{1,2,12}

¹Institut Pasteur, Unit of Human Evolutionary Genetics, 75015 Paris, France; ²Centre National de la Recherche Scientifique, CNRS URA3012, 75015 Paris, France; ³Université Pierre et Marie Curie, Cellule Pasteur UPMC, 75015 Paris, France; ⁴Institut Pasteur, Unit of Mycobacterial Genetics, 75015 Paris, France; ⁵Department of Biochemistry, Faculty of Medicine, University of Montréal, Montréal H3T 1C5, Canada; ⁶Ste-Justine Hospital Research Centre, Montréal H3T 1C5, Canada; ⁷Centre National de la Recherche Scientifique, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France; ⁸Université de Toulouse, Université Paul Sabatier, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France; ⁹Institut Pasteur, Centre d'Immunologie Humaine, 75015 Paris, France; ¹⁰Department of Paediatrics, Faculty of Medicine, University of Montréal, Montréal H3T 1C5, Canada

MicroRNAs (miRNAs) are critical regulators of gene expression, and their role in a wide variety of biological processes, including host antimicrobial defense, is increasingly well described. Consistent with their diverse functional effects, miRNA expression is highly context dependent and shows marked changes upon cellular activation. However, the genetic control of miRNA expression in response to external stimuli and the impact of such perturbations on miRNA-mediated regulatory networks at the population level remain to be determined. Here we assessed changes in miRNA expression upon *Mycobacterium tuberculosis* infection and mapped expression quantitative trait loci (eQTL) in dendritic cells from a panel of healthy individuals. Genome-wide expression profiling revealed that ~40% of miRNAs are differentially expressed upon infection. We find that the expression of 3% of miRNAs is controlled by proximate genetic factors, which are enriched in a promoter-specific histone modification associated with active transcription. Notably, we identify two infection-specific response eQTLs, for miR-326 and miR-1260, providing an initial assessment of the impact of genotype-environment interactions on miRNA molecular phenotypes. Furthermore, we show that infection coincides with a marked remodeling of the genome-wide relationships between miRNA and mRNA expression levels. This observation, supplemented by experimental data using the model of miR-29a, sheds light on the role of a set of miRNAs in cellular responses to infection. Collectively, this study increases our understanding of the genetic architecture of miRNA expression in response to infection, and highlights the wide-reaching impact of altering miRNA expression on the transcriptional landscape of a cell.

[Supplemental material is available for this article.]

The responses of host immune cells to microbial stimuli are accompanied by marked changes in gene expression, with transcriptional programs that can be shared among different microbes or be specific to each (Huang et al. 2001; Amit et al. 2009; Chevrier et al. 2011; Gat-Viks et al. 2013). The regulatory networks that control the initiation, peak magnitude, and resolution of host responses must all be properly tuned to achieve optimal immunity. In this context, microRNAs (miRNAs), a group of endogenous small RNAs (~22 nt), play a critical role in the epigenetic regulation of gene expression in eukaryotes (Ambros 2004; Bartel 2004). miRNAs bind complementary sequences of target mRNAs to promote translational repression and/or mRNA degradation (Guo et al. 2010; Huntzinger and Izaurralde 2011). For an individual target, miRNAs have only subtle regulatory effects (Hornstein and

Shomron 2006; Baek et al. 2008; Selbach et al. 2008), though a single miRNA may target over 100 genes. Over 60% of human genes are expected to be directly regulated by miRNAs (Friedman et al. 2009), with many predicted to be cotargeted by multiple miRNAs (Krek et al. 2005; Stark et al. 2005; Tsang et al. 2010). The importance of such complex and tightly regulated miRNA-mRNA networks is highlighted by the strong evolutionary constraints acting on both miRNAs and mRNA target sites, across species and within humans (Chen and Rajewsky 2006; Saunders et al. 2007; Friedman et al. 2009; Quach et al. 2009; Christodoulou et al. 2010; Berezikov 2011).

In addition to their involvement in a wide range of biological processes, including development, cell differentiation, and apo-

¹¹These authors contributed equally to this work.

¹²Corresponding author

E-mail quintana@pasteur.fr

Article published online before print. Article, supplemental material, and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.161471.113>.

© 2014 Siddle et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genome.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

ptosis, the role of miRNAs in regulating mammalian immune systems is increasingly well established (Lodish et al. 2008; O'Connell et al. 2012). MiRNAs regulate the development and function of cells of innate and adaptive immunity (Chen et al. 2004; Johnnidis et al. 2008; Lodish et al. 2008; O'Connell et al. 2012), and can have either pro-inflammatory or anti-inflammatory effects, indicating that the immune system utilizes multiple miRNAs to balance its response (O'Connell et al. 2012). Furthermore, experimental data indicate that viral, parasitic, and bacterial pathogens induce marked changes in miRNA expression in host cells (Cullen 2011; Eulalio et al. 2012). For example, activation of the innate immunity Toll-like receptor (TLR) pathway influences the expression of a well-defined group of miRNAs, while miRNAs can also regulate TLR expression as well as that of TLR signaling molecules, transcription factors, and cytokines (O'Neill et al. 2011).

There is growing evidence indicating that there is strong variation in miRNA expression in human populations, within a given cellular state, cell type, or tissue (Wang et al. 2009; Huang et al. 2011; Lu and Clark 2012; Lappalainen et al. 2013). The extent to which this variation is under genetic control (i.e., miRNA expression quantitative trait loci, miR-eQTLs) has recently begun to be investigated (Borel et al. 2011; Rantalainen et al. 2011; Gamazon et al. 2012; Parts et al. 2012; Civelek et al. 2013; Gamazon et al. 2013; Lappalainen et al. 2013). However, as has been shown for mRNAs in yeast and mammals, genetic variants can differentially affect gene expression after perturbation by various treatments or environmental variables (i.e., response eQTLs) (Gargalovic et al. 2006; Smith and Kruglyak 2008; Smirnov et al. 2009; Yang et al. 2009; Dombroski et al. 2010; Romanoski et al. 2010; Maranville et al. 2011; Barreiro et al. 2012). In humans, recent studies of protein-coding gene expression have identified response eQTLs related to oxidative stress (Romanoski et al. 2010), ionizing radiation (Smirnov et al. 2009), drug treatment (Maranville et al. 2011), and infection (Barreiro et al. 2012; Idaghdour et al. 2012). Conversely, as the few miR-eQTL studies to date have all used steady-state expression measurements, the degree of population variation in miRNA expression upon external stimulation, and the extent to which gene-environment interactions may affect the regulation of miRNA responses, remain to be determined.

Here, we aimed to dissect the genetic architecture and regulatory impact of miRNA expression in response to an external, infectious stimulus. To do so, we first characterized the population variation of miRNA transcriptional responses to infection using, as a model, *Mycobacterium tuberculosis* (MTB) infection of human dendritic cells (DCs). We then investigated the extent to which miRNA expression variation upon infection is under genetic control, providing the first attempt to map response miR-eQTLs. We next explored the relationship between miRNA and mRNA expression levels to understand how infection not only affects miRNA responses but also impacts upon broader miRNA-mediated regulatory networks. Finally, we performed miRNA gain- and loss-of-function experiments to assess the impact of altered miRNA expression on downstream transcriptional and protein responses to infection.

Results

Genomic characterization of miRNA transcriptional responses to infection

We profiled genome-wide patterns of miRNA expression in monocyte-derived DCs, untreated and after infection with a virulent strain of

MTB, from a panel of 65 healthy individuals of European descent. The presence of an infection-related response in these samples has been previously confirmed at the mRNA level, by the altered expression of genes involved in immune responses, and at the protein level, by the strong induction of cytokines known to play a critical role in protective immunity against tuberculosis (TB) (Barreiro et al. 2012). After quality checks and normalization of the data, we assessed differences in miRNA expression levels upon infection using a final set of 346 miRNAs from 63 individuals (Supplemental Fig. S1; Supplemental Methods). We found that 155 miRNAs were differentially expressed upon infection ($P < 1 \times 10^{-5}$; Bonferroni-corrected $P < 0.01$), of which 64 were up-regulated and 91 down-regulated (Fig. 1; Supplemental Table S1). Among these, down-regulated miRNAs exhibited lower fold changes than those that were up-regulated, with only three (3%), compared with 20 (31%), showing at least a twofold difference in expression levels upon infection (Fig. 1). These maximal fold changes are markedly smaller than those observed for protein-coding genes in the same system (Barreiro et al. 2012), consistent with previous observations (e.g., Sharbati et al. 2011).

The most differentially expressed miRNAs upon infection include, among others, the up-regulated miR-155, miR-132, and miR-29a, and the down-regulated miR-361-5p, miR-185, and miR-27a. These miRNAs are involved in the modulation of immune functions, such as the activation of core signaling pathways or the response to bacterial infections (O'Neill et al. 2011; Eulalio et al. 2012; Qi et al. 2012). More generally, although we found a substantial overlap between the 40% of differentially expressed miRNAs in our study and previous analyses using similar settings (Ceppi et al. 2009; Liu et al. 2009; Fu et al. 2011; Sharbati et al. 2011; Maertzdorf et al. 2012; Yi et al. 2012), we also identified distinctive signatures for some miRNAs in our model. These include the down-regulation of miR-125b and members of the miR-148




Figure 1. Changes in miRNA expression levels upon infection. Volcano plot showing the differential expression of miRNAs in DCs upon infection with MTB. Red dots denote significantly differentially expressed miRNAs whose expression changed by more than twofold following infection, whereas blue dots represent significantly differentially expressed miRNAs whose fold change (FC) was less than two. (DE) Differentially expressed.

family, which have been reported to be up-regulated upon MTB infection of macrophages (Rajaram et al. 2011) and activation of DCs with lipopolysaccharide (Liu et al. 2010), respectively. Additionally, we identified previously unreported miRNAs, such as miR-630 and miR-339-3p, as being differentially expressed upon infection. Collectively, our results are consistent with a general pro-inflammatory response (Turner et al. 2011), together with putatively cell or stimulus-dependent responses that could impact the ways in which infection is established and maintained.

Genetic regulation of miRNA expression upon infection

To identify genetic variants that affect the response to MTB infection, we mapped miR-eQTLs by testing the association between miRNA expression profiles and genome-wide genotyping data from the same 63 individuals (Methods). This sample size affords sufficient power to detect eQTLs, even in some cases where genetic variation has a moderate impact on expression levels (Supplemental Fig. S2; Supplemental Methods). To map *cis*-acting variants, we focused on SNPs located within a 200-kb window centered on the mature miRNA, and analyzed the data separately for non-infected and infected samples to discern miR-eQTLs that are shared between conditions from those that are unique to a particular state. In total, we identified miR-eQTLs for six miRNAs (miR-326, miR-338-3p, miR-451, miR-1260, miR-769-5p, and miR-130b) in infected samples, of which one (miR-338-3p) was also significant in non-infected samples, at a false discovery rate (FDR) of 0.2 (Table 1; Supplemental Table S2). These associations accounted for 20%–50% of the variance in the expression of these miRNAs.

Despite the fact that most of these miR-eQTLs displayed a significant association only in infected samples, we observed similar tendencies in the effect of the genotype on miRNA expression before and after infection (Supplemental Fig. S3). To identify response eQTLs, where a genetic variant has a stimulus-specific impact on transcript abundance, we focused on miR-eQTLs detected in one condition that had no observed effect in the other condition ($P > 0.05$). Using this threshold, we detected two putative response miR-eQTLs for miR-326 and miR-1260 (Fig. 2A). Using BRIdGE, a Bayesian approach for identifying genetic associations under different models of gene-environment interactions (Maranville et al. 2011), we confirmed five of the six associations

detected, including the two response miR-eQTLs, at a posterior probability >0.7 (FDR = 0.15; Supplemental Table S3). This approach further enabled us to identify a general interaction effect for miR-338-3p, where the miR-eQTL had a different effect in each condition (Supplemental Fig. S3).

We next searched for *trans*-eQTLs by associating miRNA expression levels with genome-wide SNPs. We identified one miRNA, miR-582-5p, whose expression was associated with a cluster of SNPs in infected samples (Fig. 2B), of which the most strongly associated was rs12523473 (Bonferroni-corrected $P = 1.49 \times 10^{-4}$). While this association lies outside the 200-kb region considered for *cis*-acting variants, its physical proximity to miR-582-5p suggests that this miR-eQTL is likely to be a long-distance *cis*-eQTL. The detection of *trans*-eQTLs suffers, however, from a high burden of multiple testing while effects may be only of modest size (Gilad et al. 2008; Majewski and Pastinen 2011; Montgomery and Dermizakis 2011). Given that regulatory variants have been observed to overlap with SNPs associated with complex phenotypes (Nica et al. 2010; Nicolae et al. 2010), we restricted our analysis to SNPs that have been suggestively associated ($P < 1 \times 10^{-5}$) with TB susceptibility by genome-wide association studies (GWAs) (Hindorf et al. 2009; Thye et al. 2010; Thye et al. 2012). In doing so, we identified a putative *trans*-eQTL for let-7i, a strongly induced, pro-inflammatory miRNA, the expression of which was associated with rs9373523 upon MTB infection (Bonferroni-corrected $P = 7.78 \times 10^{-3}$). The mechanism underlying this association remains unclear, however, that this SNP lies in an intron of the gene *STXBPS*, which is a target of let-7i, may point to a complex regulatory interaction between these transcripts.

Genomic and functional context of miR-eQTLs

To understand how eQTLs may influence miRNA expression, we studied the genomic context of the detected miR-eQTLs. We first investigated the overlap between miR-eQTLs and signatures of regulatory regions, ChIP-seq peaks and DNase I signals, reported by the ENCODE Project for human monocytes, the closest available cell-type to our model (The ENCODE Project Consortium 2012). We observed a number of overlaps with histone modifications (Supplemental Table S4). In particular, we found that the detected miR-eQTLs are significantly enriched in regions associated with the histone modification H3K4me3 ($P = 1.6 \times 10^{-3}$). That this is a mark of regulatory elements primarily associated with promoters/transcription start sites (The ENCODE Project Consortium 2012), and that three of the four SNPs overlapping such regions are located 5' of the miRNA with which they are associated (miR-1260, miR-582-5p, and miR-769-5p), further supports the functional relevance of the miR-eQTL regions in modulating miRNA expression.

To gain further insight into the putative regulatory mechanisms underlying the detected miR-eQTLs, we refined our association signals by genotype imputation (Supplemental Fig. S4; Supplemental Methods). We then searched for our miR-eQTL SNPs, and those in strong linkage disequilibrium with them, among (1) DNase I sensitivity QTLs (dsQTLs) (Degner et al. 2012), (2) mRNA-eQTLs identified in the same cellular infection model (Barreiro et al. 2012), and more generally, (3) mRNA-eQTLs identified from the International HapMap project (Xia et al. 2012). We found that two miR-eQTL SNPs for miR-451 were associated with variation in the chromatin accessibility of a nearby region (rs9279, $P = 3.77 \times 10^{-10}$, and rs2320588, $P = 9.55 \times 10^{-8}$). This DNase I-sensitive region, which lies 4 kb upstream of the precursor of miR-

Table 1. miR-eQTLs identified in *cis* for miRNA expression variation in non-infected and/or MTB-infected samples

miRNA	Non-infected samples		Infected samples	
	SNP ^a	Minimum <i>P</i> -value ^b	SNP ^a	Minimum <i>P</i> -value ^b
miR-326	rs658573	6.39×10^{-2}	rs532751	5.15×10^{-6}
miR-338-3p ^c	rs4969258	1.18×10^{-10}	rs7220048	9.21×10^{-6}
miR-451	rs9279 ^d	1.49×10^{-2}	rs9279 ^d	1.45×10^{-5}
miR-1260	rs4899651	7.36×10^{-2}	rs11159250	8.35×10^{-5}
miR-769-5p	rs759623	2.40×10^{-2}	rs8111976	1.75×10^{-4}
miR-130b	rs3788329	7.63×10^{-4}	rs3788329	2.09×10^{-4}

^aSNP for which the strongest association with miRNA expression was observed in a given condition.

^bSignificance was determined using an FDR <0.2 ($P < 4.04 \times 10^{-5}$ and 2.31×10^{-4} for non-infected and infected samples, respectively).

^cA significant eQTL was detected in both non-infected and infected conditions for this miRNA.

^dMore than one SNP showing the same minimum *P*-value for association with miRNA expression. See Supplemental Table S2 for full list of associated SNPs.




Figure 2. MiR-eQTLs upon infection. (A) Boxplots showing the detected response miR-eQTLs in *cis* for miR-326 and miR-1260, in non-infected and infected samples. (B) Regional association plot for miR-582-5p and genotyped SNPs in the region of the gene *PDE4D* showing the location of a cluster of significantly associated SNPs ~500 kb upstream of the miRNA in infected samples. An additional region, in between the detected eQTL and the miRNA, also showed a strong tendency of association; however, this did not reach genome-wide significance. All annotations are based on UCSC hg19.

451, is further associated with the binding of a number of transcription factors, especially POLR2A and GATA1 (The ENCODE Project Consortium 2012), suggesting that this region may directly regulate the transcription of miR-451. With respect to mRNAs, miR-eQTL SNPs for miR-582-5p were associated with the expression of *DEPDC1B* in *cis* (FDR = 0.05–0.11) and *PNMAL1* in *trans* (FDR < 0.2), the latter gene being a predicted target of miR-582-5p, in HapMap samples. Interestingly, four of the reported miR-eQTLs (miR-326, miR-338-3p, miR-130b, and miR-582-5p) are non-canonical intronic miRNAs (mirtrons) (Okamura et al. 2007; Ruby et al. 2007). However, no *cis*-eQTLs were identified for the corresponding host genes (*ARRB1*, *AATK*, *PPIL2*, and *PDE4D*, respectively) in the same samples. This, together with the observation that only miR-582-5p expression was moderately positively correlated with that of its host gene ($r = 0.311$; $P = 0.013$), supports the notion that mirtrons are regulated and/or processed independently of their host genes (Parts et al. 2012; Civelek et al. 2013).

Extensive remodeling of genome-wide miRNA–mRNA interactions upon infection

To understand the impact of infection on broader miRNA-mediated regulatory networks, we next investigated the genome-wide re-

lationships between variation in miRNA expression and that of protein-coding genes. To do so, we calculated Pearson correlation coefficients between the expression levels of mature miRNAs and mRNAs, obtained from the same 63 individuals, before and after infection (see Methods). We detected an overwhelming 35-fold increase in the number of significant correlations between miRNAs and mRNAs in infected samples with respect to non-infected samples (FDR < 0.005; Supplemental Table S5; Supplemental Fig. S5). Furthermore, the patterns of genome-wide correlations strongly differed between the two conditions: Correlations before infection were enriched in positive correlations ($P = 6 \times 10^{-4}$) whereas those after infection were skewed toward negative relationships ($P < 1 \times 10^{-20}$), compared with the null distribution. Specifically, only 23% of significant miRNA–mRNA correlations were negative in non-infected samples, compared with 52% in infected samples (Supplemental Fig. S6), a difference that became more pronounced when considering only the strongest correlations ($|r| > 0.7$, 9% vs. 72% in non-infected and infected samples, respectively). These trends remained similar after accounting for variation in the percentage of infected cells among individuals (Supplemental Fig. S7). Notably, we observed an enrichment in predicted miRNA targets not only among negatively ($P = 2.85 \times 10^{-5}$) but also among positively ($P = 6.45 \times 10^{-7}$) correlated genes

in infected cells. This observation is consistent with the fact that miRNAs are often involved in incoherent feed-forward loops and other complex network relationships with their targets (Hornstein and Shomron 2006; Tsang et al. 2007; Vasudevan et al. 2007; Martinez et al. 2008; Ebert and Sharp 2012; Lu and Clark 2012).

The majority of significant miRNA–mRNA correlations in both conditions were accounted for by a small number of miRNAs, as previously observed (Nunez-Iglesias et al. 2010; Su et al. 2011; Gamazon et al. 2012). Upon infection, 46 miRNAs were each correlated with at least 10 mRNAs, of which 15 were found to be associated with over 100 mRNAs and cumulatively accounted for 75% of all significant correlations (Fig. 3A; Supplemental Table S5). Furthermore, these 46 miRNAs were enriched in differentially expressed miRNAs upon infection ($P = 0.03$; $N = 30$), and included many of known importance in the regulation of the immune response (e.g., miR-155, miR-132, and miR-146a). These differentially expressed miRNAs and their significantly correlated gene sets, which were also enriched in differentially expressed genes ($P < 1 \times 10^{-20}$), formed a tightly connected regulatory network (Fig. 3B). This highlights the highly interrelated nature of miRNAs in gene regulation, consistent with their frequent cotargeting of mRNA transcripts (Krek et al. 2005; Stark et al. 2005; Tsang et al. 2010). Furthermore, among these correlated gene sets, 70% of those presenting an over/under-representation of at least one KEGG pathway and/or GO category ($FDR < 0.05$) were associated with immune-related functions. These included innate immunity signaling pathways (e.g., TLR and JAK-STAT pathways) and ac-

tivation and differentiation of lymphocytes (Supplemental Table S6), consistent with the expected functions of activated DCs. Taken together, these findings suggest that a subset of differentially expressed miRNAs may account for most of the functional associations between miRNAs and mRNAs upon MTB infection.

Characterization of the impact of miR-29a on the response to infection

To experimentally assess the impact of altered miRNA expression on both miRNA–mRNA interactions and cellular responses to MTB infection, we studied one miRNA—miR-29a—using gain- and loss-of-function approaches. We chose this miRNA because (1) it is strongly induced upon infection (Fig. 1), (2) it is among those presenting the largest number of correlated mRNAs in infected cells (Fig. 3), and (3) it has been explicitly implicated in the response to various mycobacterial infections (Fu et al. 2011; Ma et al. 2011; Sharbati et al. 2011; Eulalio et al. 2012; Yi et al. 2012; Brain et al. 2013). We thus transfected DCs with a miR-29a mimic or a miR-29 family inhibitor, as all miR-29 family members (miR-29a,b,c) share the same seed sequence, and confirmed the perturbation of miR-29 expression before and after infection with MTB (Supplemental Fig. S8; Supplemental Methods). Using genome-wide expression arrays, we identified 193 and 539 differentially expressed genes, at the steady-state, and 59 and 307, after infection, in miR-29 overexpressing and inhibited cells, respectively, compared with control-transfected cells (FDR -corrected $P < 0.01$,




Figure 3. Relationship between the levels of expression of miRNAs and protein-coding genes. (A) Barplot showing the number of significantly correlated mRNAs per miRNA in non-infected and infected samples. Only miRNAs whose expression levels were significantly correlated with those of at least 10 mRNAs are shown. A total of 47 miRNAs were correlated with at least 10 mRNAs in non-infected and/or infected conditions, with three miRNAs satisfying this criterion in both conditions. A total of 31 of these 47 miRNAs were significantly differentially expressed upon MTB infection (marked in bold). (B) Regulatory network of significantly correlated mRNAs and differentially expressed miRNAs in MTB-infected samples. Nodes represent miRNAs and mRNAs. MiRNAs are labeled when correlated with more than 100 mRNAs, with the exception of miR-150, which is independent of the main network. Edge thickness reflects the strength of the correlation between one miRNA and one mRNA transcript. Edge color represents the direction of the correlation (red, negative; blue, positive).

Supplemental Table S7). These differentially expressed genes, in particular upon miR-29a overexpression, were enriched in predicted targets of miR-29a ($P = 0.01\text{--}1 \times 10^{-20}$).

Importantly, we found that the genes whose expression was significantly correlated with that of miR-29a after infection in our previous computational analysis (Fig. 3; Supplemental Table S5) showed significantly greater changes in their expression levels with respect to noncorrelated genes in infected samples ($P = 2.31 \times 10^{-5}$ and $P = 9.34 \times 10^{-3}$ in overexpressing and inhibited cells, respectively) (Fig. 4A,B). Moreover, miR-29a predicted targets whose expression was correlated with that of this miRNA showed a significant decrease and increase in their expression levels in overexpression and inhibition experiments, respectively (Fig. 4C,D). These results support that a significant proportion of miRNA-correlated transcripts, in particular those that are predicted to be direct targets, are indeed causally regulated by miR-29.

Lastly, we assessed the impact of miR-29a on cellular responses to infection at the transcript and protein levels. Consistent with the profound effect of infection on DC maturation and function, the transcriptional response to MTB was highly concordant between control- and miR-29-transfected cells (82% and 91% overlap in mimic and inhibitor-transfected cells, respectively; FDR-corrected $P < 0.01$; Supplemental Table S7). However, a subset of differentially expressed genes upon infection responded differently following perturbation of miR-29 (64 and 235 in mimic and inhibitor-transfected cells, respectively; $P < 0.01$; Supplemental Table S7). Among these differentially responding genes, we observed an enrichment of a number of KEGG pathways and GO categories (Supplemental Table S8). In particular, genes that were differentially up-regulated following miR-29 inhibition were sig-

nificantly enriched in genes involved in cytokine–cytokine receptor interaction and TLR signaling pathways. At the protein level, we similarly observed a major effect of infection, with a strong induction of many cytokines that play a major role in the DC response to infection, including TNF, IL12B, and IL10 (Giacomini et al. 2001; Hickman et al. 2002; Supplemental Table S9). However, the inhibition of miR-29 promoted an enhanced cytokine response, as attested to by the significantly higher induction of 12 cytokines and chemokines, with respect to control-transfected samples, after infection (Fig. 5A). Notably, three of these cytokines are miR-29a predicted targets (*IL12B*, *IL2RA*, and *CXCL10*), consistent with a direct effect of miR-29 on cytokine responses. Furthermore, despite the more modest effect of miR-29a overexpression on cytokine levels (Supplemental Table S9), one of these proteins, *CXCL10*, was significantly down-regulated compared with control-transfected samples (Fig. 5B), providing strong support for a direct regulation of this chemokine by miR-29 in MTB-infected DCs.

Discussion

Identifying genetic variants that affect miRNA expression in the presence or absence of specific environmental variables can provide insights into the mechanisms underlying variation in transcript abundance. We first showed that the expression of 3% of miRNAs is explained by proximate genetic factors, consistent with several previous estimates (Rantalainen et al. 2011; Parts et al. 2012; Civelek et al. 2013). That 9% of protein-coding genes harbor *cis*-regulatory variants in the same samples, at an FDR of only 0.01 (Barreiro et al. 2012), supports the notion that miRNA expression is under less genetic control than that of mRNAs (Su et al. 2011; Civelek et al. 2013; Lappalainen et al. 2013). The fewer eQTLs detected for miRNAs may reflect a lower permissibility of large changes in their expression, because these would have extensive consequences on the multiple genes and pathways with which miRNAs are associated. Moreover, given the strong conservation observed in miRNA sequences and expression patterns (Quach et al. 2009; Christodoulou et al. 2010; Berezikov 2011), one may also anticipate greater sequence conservation in their regulatory regions, and hence a lower dependence of miRNA expression on proximate genetic variants.

Although several studies have mapped gene–environment interactions for expression phenotypes of protein-coding genes (Smirnov et al. 2009; Romanoski et al. 2010; Maranville et al. 2011; Barreiro et al. 2012; Idaghdour et al. 2012), there has been no effort to characterize the genetic architecture of miRNA expression upon perturbation by external stimuli. Here, we provide evidence of genotype-by-infection interactions that affect miRNA expression variation. The strongest signal among response miR-eQTLs is that observed for miR-326—associated with an eQTL exclusively upon infection (Fig. 2A).




Figure 4. Functional validation of miRNA–mRNA relationships using miR-29a gain- and loss-of-function experiments. (A,B) Boxplots showing absolute fold changes in genome-wide mRNA levels of cells transfected with either an miR-29a mimic (A) or an miR-29 inhibitor (B) and subsequently infected with MTB. (C,D) Cumulative distributions of changes in genome-wide mRNA levels after transfection with the mimic (C) or the inhibitor (D) in MTB-infected cells.




Figure 5. Inhibition of miR-29 up-regulates the secretion of multiple cytokines in MTB-infected DCs. Cytokine and chemokine concentrations in culture supernatants from transfected, infected cells were analyzed by multiplex bead immunoassay. (A) Relative cytokine/chemokine concentrations in miR-29 inhibitor-transfected cells compared with control-transfected samples \pm SEM for duplicates of infection performed on four different donors. MiR-29 inhibition significantly increased the expression of 12 out of 22 cytokines. (***) $P < 0.01$. (B) Relative concentrations of the chemokine CXCL10 for mimic- and inhibitor-transfected cells, with respect to control-transfected samples, for duplicates of infection performed on four different donors.

The increased expression of miR-326 in T cells promotes the generation of Th17 cells and is associated with the severity of autoimmune disease (Du et al. 2009). In MTB infection, a shift toward a stronger induction of the Th17 pathway has been associated with excessive neutrophil recruitment, tissue damage, and increased disease severity (Torrado and Cooper 2010; Jurado et al. 2012). The down-regulation of miR-326 that we observed upon infection points to a direct link between this miRNA and DC responses to MTB infection. Furthermore, that a subset of individuals characterized by the AA genotype show higher miR-326 expression after infection (~10% of Europeans) (Fig. 2A), which may decrease protective immunity, suggests that regulatory variation at this locus might ultimately impact inter-individual differences in the host response to MTB. This example, together with the infection-dependent eQTL for miR-1260 expression and the interaction effect associated with miR-338-3p, provides experimentally testable hypotheses concerning the role of these miRNAs in immune responses and TB pathogenesis.

The integration of genome-wide expression data from miRNAs and mRNAs highlights the complexity of the miRNA-mediated regulatory system. Although differences in miRNA-mRNA relationships have been reported in diseased and healthy individuals or distinct cell subsets (Cheng et al. 2009; Nunez-Iglesias et al. 2010; Allantaz et al. 2012; Zhang et al. 2012), a systematic study of the impact of an external stimulus on these relationships has been lacking. Our findings showed that infection is accompanied by a rapid and strong remodeling of miRNA-mediated regulatory networks, with a shift toward negative miRNA-mRNA correlations. Such a marked shift, largely accounted for by a small number of differentially expressed miRNAs, emphasizes the wide-reaching impact of a subset of miRNAs in the transcriptional response of a cell to infection.

Through our gain- and loss-of-function experiments, using the model of miR-29a, we have confirmed that the miR-29a-correlated mRNAs detected by our computational analysis are associated with significantly greater changes in expression levels upon perturbation of miR-29 expression in infected cells. This points to a general causal regulation, direct or indirect, of correlated genes by miR-29. That not all genes showed such a change, however, is consistent with the expectation that miRNA-mRNA interactions reflect the coregulation of miRNA-mRNA pairs and/or miRNA sensing as well as signaling (Su et al. 2011). In addition, positively

correlated miR-29a predicted targets displayed changes in their expression levels that are consistent with canonical miRNA-mediated repression, lending experimental support to the importance of regulatory loops in miRNA-mRNA interactions (Tsang et al. 2007; Martinez et al. 2008; Ebert and Sharp 2012). Given the large number of positive correlations that we and others report (Martinez et al. 2008; Nunez-Iglesias et al. 2010; Su et al. 2011; Lappalainen et al. 2013), and the enrichment in miRNA predicted targets observed among them, it thus seems likely that feedforward and feedback loops are widespread mechanisms in miRNA-mediated regulatory responses in the context of infection.

Our functional study of miR-29a has also provided new insight into the role of this miRNA in DC functions and responses to MTB infection. First, we observed more differentially expressed genes between miR-29- and control-transfected cells in non-infected conditions, with respect to infected samples. This suggests that, upon infection, miR-29 may drive more focused changes in a smaller set of genes. Second, not only was miR-29a strongly up-regulated in our setting but, most importantly, it had a substantial impact on cytokine secretion in response to infection. In particular, the secretion of CXCL10 is consistent with a direct, repressive effect of miR-29 on this chemokine, which may impact the recruitment of Th1 cells upon MTB infection (Giacomini et al. 2006).

In conclusion, our study has provided an initial assessment of the impact of genotype-environment interactions on miRNA molecular phenotypes by identifying response miR-eQTLs related to infection. This, together with the observed infection-dependent shift of miRNA-mRNA relationships driven by a few miRNAs, such as miR-29a, paves the way for additional studies to evaluate the biological contribution of these miRNAs to immunity to infection and disease outcome.

Methods

Samples and miRNA expression analyses

Blood samples were obtained from 65 healthy donors from Research Blood Components. Signed, written consent was obtained from all individuals, in accordance with the company's independent ethics committee approval. Isolation and infection of DCs with *Mycobacterium tuberculosis* (H37Rv) for 18 h, RNA extraction

and quality verification, DNA extraction, and genome-wide genotyping have been previously described (Barreiro et al. 2012). Genome-wide miRNA expression was profiled using the Agilent Human miRNA microarray (Release 16.0). After a series of quality checks, preprocessing, and normalization of the data (Supplemental Methods), we identified differentially expressed miRNAs upon MTB infection by applying a linear model with a fixed effect for MTB treatment, implemented in the Bioconductor package *limma* (Smyth 2004).

Mapping of expression quantitative trait loci (eQTLs)

Associations between SNP genotypes (GEO accession number GSE34588) (Barreiro et al. 2012) and miRNA expression levels were calculated using a linear regression model, assuming an additive effect of alleles on expression, in infected and non-infected samples. We improved the power to detect eQTLs by quantile normalization and regression of a number of principal components, to account for unknown confounders (Supplemental Fig. S9). FDRs were estimated by comparing the observed to a null distribution, generated using the lowest *P*-values observed for each miRNA in 100 permutations of expression values (Pickrell et al. 2010; Barreiro et al. 2012). Genotype-treatment interaction effects were detected by Bayesian regression with the software BRIDGE (Maranville et al. 2011). For *trans*-eQTLs, associations were calculated with both genome-wide genotyping data from the same individuals (Barreiro et al. 2012) and a subset of SNPs previously identified as susceptibility loci for TB by GWAs (<http://www.genome.gov/26525384/>) (Hindorff et al. 2009). Multiple testing corrections were performed using a Bonferroni correction at the 95% significance level. The overlap of miR-eQTLs with active genomic regions was assessed using data from the ENCODE Project (<http://encodeproject.org/ENCODE/>) (The ENCODE Project Consortium 2012). Enrichments were calculated using a Fisher's exact test. For the fine-mapping of miR-eQTL regions, we imputed genotypes for SNPs not present on our genotyping array with IMPUTE2 (Howie et al. 2009), using integrated haplotype data from Phase 1 of the 1000 Genomes Project (The 1000 Genomes Project Consortium 2012). For details, see the Supplemental Methods.

Correlation of miRNA and mRNA expression levels

We calculated Pearson correlation coefficients between quantile normalized expression levels of miRNAs and mRNAs detected in at least 50% of samples in at least one condition. As clustered miRNAs show correlated expression profiles (Supplemental Fig. S10), we considered only the most abundant member of each pre-miRNA ($N = 221$). Expression levels of 12,958 protein-coding genes were previously obtained from the same 63 individuals (Barreiro et al. 2012). Significant miRNA–mRNA correlations were determined at an FDR < 0.005 based on a null distribution of 1000 permutations and differences between the means of real and null distributions were determined using a *t*-test. Predicted targets of miRNAs were obtained from TargetScan (v6.2) (Friedman et al. 2009). The enrichment of predicted targets of all miRNAs in the network among all miRNA-correlated genes was calculated using a Fisher's exact test. Enrichments of functional Gene Ontology categories and KEGG pathways among the same gene sets were computed using GeneTrail (Backes et al. 2007). We used all 12,958 expressed genes as a background set for over/under-representation analyses of correlated gene sets. Enrichment *P*-values were calculated using a hypergeometric test and we used the Benjamini and Hochberg (1995) approach to correct for multiple testing. Networks were visualized using Cytoscape (Cline et al. 2007).

Functional analyses of miR-29a using gain- and loss-of-function approaches

Immature DCs from four unrelated individuals were transfected on day 5 using HiPerFect transfection reagent. MiRCURY LNA Power Inhibitors were purchased from Exiqon (miR-29 family 460039, control 199020-00) and miRIDIAN microRNA mimics from Thermo Fisher (miR-29a C-300504-07, control CN-001000-01). Transfection efficiency was assessed by flow cytometry using a fluorescently labeled control oligonucleotide (Exiqon, 199020-04), and found to be on average 77% (Supplemental Fig. S11). Transfected cells were then infected for 24 h with MTB (H37Rv) (Supplemental Fig. S12). MiR-29 expression upon MTB infection and the extent of miR-29 perturbation in transfected cells were quantified by quantitative real-time PCR (qPCR). For gene expression analysis, genome-wide profiling of non-infected and MTB-infected samples was obtained by hybridizing RNA to Illumina HumanHT-12 v4 Expression BeadChip arrays. After a series of quality checks and preprocessing steps, differential expression analysis was performed using the Bioconductor package *limma* (Smyth 2004). For quantification of cytokine and chemokine levels, we measured supernatant levels of 25 cytokines/chemokines using the Human Cytokine Magnetic 25-Plex Panel (Invitrogen). Differences in secretion levels between conditions were calculated using a Wilcoxon paired rank sum test. For details, see the Supplemental Methods.

Data access

The miRNA and mRNA expression data reported in this manuscript have been submitted to the NCBI Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) under accession numbers GSE49951 and GSE53143, respectively.

Acknowledgments

We thank Robin Friedman for critical reading of the manuscript and useful suggestions; Yoav Gilad for facilitating access to mRNA expression data; and Maud Fagny, Eddie Loh, and John Marioni for helpful discussions. The laboratory of L.Q.-M. has received funding from the Institut Pasteur, the Centre Nationale de la Recherche Scientifique (CNRS), the French government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (grant no. ANR-10-LABX-62-IBEID), and the European Research Council under the European Union's Seventh Framework Programme (FP/2007–2013)/ERC grant agreement no. 281297. The laboratory of L.B.B. has received funding from the Canadian Institute of Health Research (grant nos. 232519 and 285969) and the Human Frontiers Science Program (grant no. CDA00025-2012). L.B.B. is a scholar of the Fonds de la Recherche en Santé du Québec. The laboratory of L.T. and B.G. has received funding from the National Institutes of Health (grant no. NIH AI087658) and the European Commission within the 7th Framework Programme (grant no. HEALTH-F3-2009-241745). K.J.S. is a scholar of the Pasteur–Paris University (PPU) International PhD program and was supported by a stipend from the Direction Générale de l'Armement (DGA). Y.N. was supported by a fellowship from the Réseau de médecine génétique appliquée, Fonds de recherche du Québec–Santé (FRQS), and the Instituts de recherche en santé du Canada (IRSC, subvention no. TGF-96109).

Author contributions: The study was designed by K.J.S., L.B.B., and L.Q.-M. Computational analyses were performed by K.J.S. with contributions and input from Y.N., E.P., G.L., L.B.B., and L.Q.-M. Functional inhibition and overexpression experiments

were performed by M.D. and differentiation and infection of dendritic cells by L.T., with contributions and guidance from J.P., G.L.-V., V.L., and O.N. B.G. contributed with materials and tools. The manuscript was written by K.J.S. and L.Q.-M. with input from all authors.

References

- The 1000 Genomes Project Consortium. 2012. An integrated map of genetic variation from 1,092 human genomes. *Nature* **491**: 56–65.
- Allantaz F, Cheng DT, Bergauer T, Ravindran P, Rossier MF, Ebeling M, Badi L, Reis B, Bitter H, D'Asaro M, et al. 2012. Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression. *PLoS ONE* **7**: e29979.
- Ambros V. 2004. The functions of animal microRNAs. *Nature* **431**: 350–355.
- Amit I, Garber M, Chevrier N, Leite AP, Donner Y, Eisenhaure T, Guttman M, Grenier JK, Li W, Zuk O, et al. 2009. Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. *Science* **326**: 257–263.
- Backes C, Keller A, Kuentzer J, Kneissl B, Comtesse N, Elnakady YA, Muller R, Meese E, Lenhof HP. 2007. GeneTrail—advanced gene set enrichment analysis. *Nucleic Acids Res* **35**: W186–W192.
- Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. 2008. The impact of microRNAs on protein output. *Nature* **455**: 64–71.
- Barreiro LB, Tailleux L, Pai AA, Gicquel B, Marioni JC, Gilad Y. 2012. Deciphering the genetic architecture of variation in the immune response to *Mycobacterium tuberculosis* infection. *Proc Natl Acad Sci* **109**: 1204–1209.
- Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* **116**: 281–297.
- Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate—a practical and powerful approach to multiple testing. *J R Stat Soc Ser B Methodol* **57**: 289–300.
- Berezikov E. 2011. Evolution of microRNA diversity and regulation in animals. *Nat Rev Genet* **12**: 846–860.
- Borel C, Deutsch S, Letourneau A, Migliavacca E, Montgomery SB, Dimas AS, Vajnar CE, Attar H, Gagnebin M, Gehrig C, et al. 2011. Identification of *cis*- and *trans*-regulatory variation modulating microRNA expression levels in human fibroblasts. *Genome Res* **21**: 68–73.
- Brain O, Owens BM, Pichulik T, Allan P, Khatamzas E, Leslie A, Steevens T, Sharma S, Mayer A, Catuneanu AM, et al. 2013. The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release. *Immunity* **39**: 521–536.
- Ceppi M, Pereira PM, Dunand-Sauthier I, Barras E, Reith W, Santos MA, Pierre P. 2009. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. *Proc Natl Acad Sci* **106**: 2735–2740.
- Chen K, Rajewsky N. 2006. Natural selection on human microRNA binding sites inferred from SNP data. *Nat Genet* **38**: 1452–1456.
- Chen CZ, Li L, Lodish HF, Bartel DP. 2004. MicroRNAs modulate hematopoietic lineage differentiation. *Science* **303**: 83–86.
- Cheng C, Fu X, Alves P, Gerstein M. 2009. mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. *Genome Biol* **10**: R90.
- Chevrier N, Mertins P, Artyomov MN, Shalek AK, Iannaccone M, Ciaccio MF, Gat-Viks I, Tonti E, DeGrace MM, Clauser KR, et al. 2011. Systematic discovery of TLR signaling components delineates viral-sensing circuits. *Cell* **147**: 853–867.
- Christodoulou F, Raible F, Tomer R, Simakov O, Trachana K, Klaus S, Snyman H, Hannon GJ, Bork P, Arendt D. 2010. Ancient animal microRNAs and the evolution of tissue identity. *Nature* **463**: 1084–1088.
- Civelek M, Hagopian R, Pan C, Che N, Yang WP, Kayne PS, Saleem NK, Cederberg H, Kuusisto J, Gargalovic PS, et al. 2013. Genetic regulation of human adipose microRNA expression and its consequences for metabolic traits. *Hum Mol Genet* **22**: 3023–3037.
- Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christas R, Avila-Campillo I, Creech M, Gross B, et al. 2007. Integration of biological networks and gene expression data using Cytoscape. *Nat Protoc* **2**: 2366–2382.
- Cullen BR. 2011. Viruses and microRNAs: RISCy interactions with serious consequences. *Genes Dev* **25**: 1881–1894.
- Degner JF, Pai AA, Pique-Regi R, Veyrieras JB, Gaffney DJ, Pickrel JK, De Leon S, Michellini K, Lewellen N, Crawford GE, et al. 2012. DNase I sensitivity QTLs are a major determinant of human expression variation. *Nature* **482**: 390–394.
- Dombroski BA, Nayak RR, Ewens KG, Ankeny W, Cheung VG, Spielman RS. 2010. Gene expression and genetic variation in response to endoplasmic reticulum stress in human cells. *Am J Hum Genet* **86**: 719–729.
- Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S, Li Z, Wu Z, Pei G. 2009. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. *Nat Immunol* **10**: 1252–1259.
- Ebert MS, Sharp PA. 2012. Roles for microRNAs in conferring robustness to biological processes. *Cell* **149**: 515–524.
- The ENCODE Project Consortium. 2012. An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**: 57–74.
- Eulalio J, Schulte L, Vogel J. 2012. The mammalian microRNA response to bacterial infections. *RNA Biol* **9**: 742–750.
- Friedman RC, Farh KK, Burge CB, Bartel DP. 2009. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res* **19**: 92–105.
- Fu Y, Yi Z, Wu X, Li J, Xu F. 2011. Circulating microRNAs in patients with active pulmonary tuberculosis. *J Clin Microbiol* **49**: 4246–4251.
- Gamazon ER, Ziliak D, Im HK, LaCroix B, Park DS, Cox NJ, Huang RS. 2012. Genetic architecture of microRNA expression: implications for the transcriptome and complex traits. *Am J Hum Genet* **90**: 1046–1063.
- Gamazon ER, Innocenti F, Wei R, Wang L, Zhang M, Mirkov S, Ramirez J, Huang RS, Cox NJ, Ratain MJ, et al. 2013. A genome-wide integrative study of microRNAs in human liver. *BMC Genomics* **14**: 395.
- Gargalovic PS, Imura M, Zhang B, Gharavi NM, Clark MJ, Pagnon J, Yang WP, He A, Truong A, Patel S, et al. 2006. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. *Proc Natl Acad Sci* **103**: 12741–12746.
- Gat-Viks I, Chevrier N, Wilentzik R, Eisenhaure T, Raychowdhury R, Steuerman Y, Shalek AK, Hacohen N, Amit I, Regev A. 2013. Deciphering molecular circuits from genetic variation underlying transcriptional responsiveness to stimuli. *Nat Biotechnol* **31**: 342–349.
- Giacomini E, Iona E, Ferroni L, Miettinen M, Fattorini L, Orefici G, Julkunen I, Coccia EM. 2001. Infection of human macrophages and dendritic cells with *Mycobacterium tuberculosis* induces a differential cytokine gene expression that modulates T cell response. *J Immunol* **166**: 7033–7041.
- Giacomini E, Sotolongo A, Iona E, Severa M, Remoli ME, Gafa V, Lande R, Fattorini L, Smith I, Manganelli R, et al. 2006. Infection of human dendritic cells with a *Mycobacterium tuberculosis* sigE mutant stimulates production of high levels of interleukin-10 but low levels of CXCL10: impact on the T-cell response. *Infect Immun* **74**: 3296–3304.
- Gilad Y, Rifkin SA, Pritchard JK. 2008. Revealing the architecture of gene regulation: the promise of eQTL studies. *Trends Genet* **24**: 408–415.
- Guo H, Ingolia NT, Weissman JS, Bartel DP. 2010. Mammalian microRNAs predominantly act to decrease target mRNA levels. *Nature* **466**: 835–840.
- Hickman SP, Chan J, Salgame P. 2002. *Mycobacterium tuberculosis* induces differential cytokine production from dendritic cells and macrophages with divergent effects on naive T cell polarization. *J Immunol* **168**: 4636–4642.
- Hindorf LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA. 2009. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci* **106**: 9362–9367.
- Hornstein E, Shomron N. 2006. Canalization of development by microRNAs. *Nat Genet* (Suppl) **38**: S20–S24.
- Howie BN, Donnelly P, Marchini J. 2009. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet* **5**: e1000529.
- Huang Q, Liu D, Majewski P, Schulte LC, Korn JM, Young RA, Lander ES, Hacohen N. 2001. The plasticity of dendritic cell responses to pathogens and their components. *Science* **294**: 870–875.
- Huang RS, Gamazon ER, Ziliak D, Wen Y, Im HK, Zhang W, Wing C, Duan S, Bleibel WK, Cox NJ, et al. 2011. Population differences in microRNA expression and biological implications. *RNA Biol* **8**: 692–701.
- Huntzinger E, Izaurralde E. 2011. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. *Nat Rev Genet* **12**: 99–110.
- Idaghdour Y, Quinlan J, Goulet JP, Berghout J, Gbeha E, Bruat V, de Malliard T, Grenier JC, Gomez S, Gros P, et al. 2012. Evidence for additive and interaction effects of host genotype and infection in malaria. *Proc Natl Acad Sci* **109**: 16786–16793.
- Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, Brummelkamp TR, Fleming MD, Camargo FD. 2008. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. *Nature* **451**: 1125–1129.
- Jurado JO, Pasquinelli V, Alvarez IB, Pena D, Rovetta AI, Tateosian NL, Romeo HE, Musella RM, Palmero D, Chuluyán HE, et al. 2012. IL-17 and IFN- γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease. *J Leukoc Biol* **91**: 991–1002.
- Krek A, Grun D, Poy MN, Wolf R, Rosenber L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al. 2005. Combinatorial microRNA target predictions. *Nat Genet* **37**: 495–500.

- Lappalainen T, Sammeth M, Friedlander MR, 't Hoen PA, Monlong J, Rivas MA, Gonzalez-Porta M, Kurbatova N, Griebel T, Ferreira PG, et al. 2013. Transcriptome and genome sequencing uncovers functional variation in humans. *Nature* **501**: 506–511.
- Liu G, Friggeri A, Yang Y, Park YJ, Tsuruta Y, Abraham E. 2009. miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. *Proc Natl Acad Sci* **106**: 15819–15824.
- Liu X, Zhan Z, Xu L, Ma F, Li D, Guo Z, Li N, Cao X. 2010. MicroRNA-148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKII α . *J Immunol* **185**: 7244–7251.
- Lodish HF, Zhou B, Liu G, Chen CZ. 2008. Micromanagement of the immune system by microRNAs. *Nat Rev Immunol* **8**: 120–130.
- Lu J, Clark AG. 2012. Impact of microRNA regulation on variation in human gene expression. *Genome Res* **22**: 1243–1254.
- Ma F, Xu S, Liu X, Zhang Q, Xu X, Liu M, Hua M, Li N, Yao H, Cao X. 2011. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon- γ . *Nat Immunol* **12**: 861–869.
- Maertzdorf J, Weiner J III, Mollenkopf HJ, Bauer T, Prasse A, Muller-Quernheim J, Kaufmann SH. 2012. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. *Proc Natl Acad Sci* **109**: 7853–7858.
- Majewski J, Pastinen T. 2011. The study of eQTL variations by RNA-seq: from SNPs to phenotypes. *Trends Genet* **27**: 72–79.
- Maranville JC, Luca F, Richards AL, Wen X, Witonsky DB, Baxter S, Stephens M, Di Rienzo A. 2011. Interactions between glucocorticoid treatment and *cis*-regulatory polymorphisms contribute to cellular response phenotypes. *PLoS Genet* **7**: e1002162.
- Martinez NJ, Ow MC, Barrasa MI, Hammell M, Sequerra R, Doucette-Stamm L, Roth FP, Ambros VR, Walhout AJ. 2008. A *C. elegans* genome-scale microRNA network contains composite feedback motifs with high flux capacity. *Genes Dev* **22**: 2535–2549.
- Montgomery SB, Dermitzakis ET. 2011. From expression QTLs to personalized transcriptomics. *Nat Rev Genet* **12**: 277–282.
- Nica AC, Montgomery SB, Dimas AS, Stranger BE, Beazley C, Barroso I, Dermitzakis ET. 2010. Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. *PLoS Genet* **6**: e1000895.
- Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. 2010. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. *PLoS Genet* **6**: e1000888.
- Nunez-Iglesias J, Liu CC, Morgan TE, Finch CE, Zhou XJ. 2010. Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation. *PLoS ONE* **5**: e8898.
- O'Connell RM, Rao DS, Baltimore D. 2012. microRNA regulation of inflammatory responses. *Annu Rev Immunol* **30**: 295–312.
- Okamura K, Hagen JW, Duan H, Tyler DM, Lai EC. 2007. The mirtron pathway generates microRNA-class regulatory RNAs in *Drosophila*. *Cell* **130**: 89–100.
- O'Neill LA, Sheedy FJ, McCoy CE. 2011. MicroRNAs: the fine-tuners of Toll-like receptor signalling. *Nat Rev Immunol* **11**: 163–175.
- Parts L, Hedman AK, Keildson S, Knights AJ, Abreu-Goodger C, van de Bunt M, Guerra-Assuncao JA, Bartonicek N, van Dongen S, Magi R, et al. 2012. Extent, causes, and consequences of small RNA expression variation in human adipose tissue. *PLoS Genet* **8**: e1002704.
- Pickrell JK, Marioni JC, Pai AA, Degner JF, Engelhardt BE, Nkadori E, Veyrieras JB, Stephens M, Gilad Y, Pritchard JK. 2010. Understanding mechanisms underlying human gene expression variation with RNA sequencing. *Nature* **464**: 768–772.
- Qi Y, Cui L, Ge Y, Shi Z, Zhao K, Guo X, Yang D, Yu H, Cui L, Shan Y, et al. 2012. Altered serum microRNAs as biomarkers for the early diagnosis of pulmonary tuberculosis infection. *BMC Infect Dis* **12**: 384.
- Quach H, Barreiro LB, Laval G, Zidane N, Patin E, Kidd KK, Kidd JR, Bouchier C, Veuille M, Antoniewski C, et al. 2009. Signatures of purifying and local positive selection in human miRNAs. *Am J Hum Genet* **84**: 316–327.
- Rajaram MV, Ni B, Morris JD, Brooks MN, Carlson TK, Bakthavachalu B, Schoenberg DR, Torrelles JB, Schlesinger LS. 2011. *Mycobacterium tuberculosis* lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. *Proc Natl Acad Sci* **108**: 17408–17413.
- Rantalainen M, Herrera BM, Nicholson G, Bowden R, Wills QF, Min JL, Neville MJ, Barrett A, Allen M, Rayner NW, et al. 2011. MicroRNA expression in abdominal and gluteal adipose tissue is associated with mRNA expression levels and partly genetically driven. *PLoS ONE* **6**: e27338.
- Romanoski CE, Lee S, Kim MJ, Ingram-Drake L, Plaisier CL, Yordanova R, Tilford C, Guan B, He A, Gargalovic PS, et al. 2010. Systems genetics analysis of gene-by-environment interactions in human cells. *Am J Hum Genet* **86**: 399–410.
- Ruby JG, Jan CH, Bartel DP. 2007. Intronic microRNA precursors that bypass Drosha processing. *Nature* **448**: 83–86.
- Saunders MA, Liang H, Li WH. 2007. Human polymorphism at microRNAs and microRNA target sites. *Proc Natl Acad Sci* **104**: 3300–3305.
- Selbach M, Schwanhauss B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. 2008. Widespread changes in protein synthesis induced by microRNAs. *Nature* **455**: 58–63.
- Sharbati J, Lewin A, Kutz-Lohroff B, Kamal E, Einspanier R, Sharbati S. 2011. Integrated microRNA-mRNA-analysis of human monocyte derived macrophages upon *Mycobacterium avium* subsp. *hominissuis* infection. *PLoS ONE* **6**: e20258.
- Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG. 2009. Genetic analysis of radiation-induced changes in human gene expression. *Nature* **459**: 587–591.
- Smith EN, Kruglyak L. 2008. Gene-environment interaction in yeast gene expression. *PLoS Biol* **6**: e83.
- Smyth GK. 2004. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol* **3**: Article 3.
- Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM. 2005. Animal microRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution. *Cell* **123**: 1133–1146.
- Su WL, Kleinhanz RR, Schadt EE. 2011. Characterizing the role of miRNAs within gene regulatory networks using integrative genomics techniques. *Mol Syst Biol* **7**: 490.
- Thye T, Vannberg FO, Wong SH, Owusu-Dabo E, Osei I, Gyaopong J, Sirugo G, Sisay-Joof F, Enimil A, Chinbuah MA, et al. 2010. Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. *Nat Genet* **42**: 739–741.
- Thye T, Owusu-Dabo E, Vannberg FO, van Crevel R, Curtis J, Sahiratmadja E, Balabanova Y, Ehmen C, Muntau B, Ruge G, et al. 2012. Common variants at 11p13 are associated with susceptibility to tuberculosis. *Nat Genet* **44**: 257–259.
- Torrado E, Cooper AM. 2010. IL-17 and Th17 cells in tuberculosis. *Cytokine Growth Factor Rev* **21**: 455–462.
- Tsang J, Zhu J, van Oudenaarden A. 2007. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. *Mol Cell* **26**: 753–767.
- Tsang JS, Ebert MS, van Oudenaarden A. 2010. Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures. *Mol Cell* **38**: 140–153.
- Turner ML, Schnorfeil FM, Brocker T. 2011. MicroRNAs regulate dendritic cell differentiation and function. *J Immunol* **187**: 3911–3917.
- Vasudevan S, Tong Y, Steitz JA. 2007. Switching from repression to activation: microRNAs can up-regulate translation. *Science* **318**: 1931–1934.
- Wang L, Oberg AL, Asmann YW, Sicotte H, McDonnell SK, Riska SM, Liu W, Steer CJ, Subramanian S, Cunningham JM, et al. 2009. Genome-wide transcriptional profiling reveals microRNA-correlated genes and biological processes in human lymphoblastoid cell lines. *PLoS ONE* **4**: e5878.
- Xia K, Shabalina AA, Huang S, Madar V, Zhou YH, Wang W, Zou F, Sun W, Sullivan PF, Wright FA. 2012. seeQTL: a searchable database for human eQTLs. *Bioinformatics* **28**: 451–452.
- Yang IV, Wade CM, Kang HM, Alper S, Rutledge H, Lackford B, Eskin E, Daly MJ, Schwartz DA. 2009. Identification of novel genes that mediate innate immunity using inbred mice. *Genetics* **183**: 1535–1544.
- Yi Z, Fu Y, Ji R, Li R, Guan Z. 2012. Altered microRNA signatures in sputum of patients with active pulmonary tuberculosis. *PLoS ONE* **7**: e43184.
- Zhang W, Edwards A, Fan W, Flemington EK, Zhang K. 2012. miRNA-mRNA correlation-network modules in human prostate cancer and the differences between primary and metastatic tumor subtypes. *PLoS ONE* **7**: e40130.

Received June 3, 2013; accepted in revised form January 22, 2014.